GleamWall
中文EN

RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1742927 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY50.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-128.3%
ROA-68.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets29.5%
Debt / equity0.00x
Current ratio3.39x
Interest coverage-2,310.59x

Cash quality & payout

Operating cash flow / net income1.23x
Accruals ratio15.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$11.71M$22.91M
SG&A expense$8.49M$7.89M
Operating income-$20.20M-$30.80M
Interest expense$13,402$18,497
Pretax income-$19.85M-$29.90M
Income tax$18,889$19,514
Net income-$19.86M-$29.92M
EPS (basic)-5.48-17.73
EPS (diluted)——
Balance sheet
Cash & equivalents$14.44M$13.48M
Current assets$15.10M$14.68M
Total assets$15.92M$15.50M
Current liabilities$7.28M$14.60M
Short-term debt$406,875$458,154
Total liabilities$7.28M$14.69M
Shareholders' equity$8.65M$812,572
Shares outstanding5.87M2.36M
Cash flow statement
Operating cash flow-$24.59M-$33.54M
Financing cash flow$25.56M$23.65M
Stock-based compensation$2.23M$1.63M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.